Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience [0.03%]
Teclistamab对复发/难治性多发性骨髓瘤患者的疗效和安全性：一项真实世界研究体验
Danai Dima,James A Davis,Nausheen Ahmed et al.
Danai Dima et al.
Teclistamab is a B cell maturation antigen (BCMA)-directed bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase I/II MajesTEC-1 trial. Here we report clinical outcomes with standard-of-care ...
Pharmacotherapy for the Prevention of Depression and Behavioral Side Effects in Hematopoietic Stem Cell Transplantation Patients [0.03%]
用于预防血液病干细胞移植病人抑郁和行为异常的药物治疗
Patricia Mumby,William Adams,Scott Smith et al.
Patricia Mumby et al.
Depression and decreased quality of life (QoL) develop in approximately 30% of nondepressed hematopoietic stem cell transplantation (HSCT) recipients early after transplantation. To potentially prevent this complication, we conducted a pros...
Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children [0.03%]
同情使用Narsoplimab治疗儿童严重的难治性移植相关血栓性微血管病
Michelle L Schoettler,Seema Patel,Elyse Bryson et al.
Michelle L Schoettler et al.
Transplant-associated thrombotic microangiopathy (TA-TMA) is a common and potentially severe complication of hematopoietic cell transplantation. TA-TMA-directed therapy with eculizumab, a complement C5 inhibitor, has resulted in a survival ...
Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma [0.03%]
虚弱状态对复发/难治性多发性骨髓瘤患者接受嵌合抗原受体T细胞治疗后结果的影响
James A Davis,Danai Dima,Nausheen Ahmed et al.
James A Davis et al.
The literature is limited regarding outcomes in older adults and frail patients receiving BCMA-directed chimeric antigen receptor T cell therapy (CAR-T) for relapsed or refractory multiple myeloma. Here we describe the safety and efficacy o...
Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis [0.03%]
B细胞血液恶性肿瘤患者接受嵌合抗原受体T细胞治疗时多次SARS-CoV-2疫苗接种的有效性： contemporary队列分析
Muhammad Bilal Abid,Micah Rubin,Aniko Szabo et al.
Muhammad Bilal Abid et al.
The mortality due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) approaches 40% in recipients of chimeric antigen receptor (CAR) T cell therapy (CAR-T). The efficacy of repeated vaccine doses, including bivalent boosters, r...
Development of a Pipeline for Removing Allergy Labels in Patients Undergoing Hematopoietic Stem Cell Transplantation [0.03%]
用于在进行造血干细胞移植的患者中去除过敏标识的流程开发
Lauren E Merz,George X Huang,Geneva D Mehta et al.
Lauren E Merz et al.
Penicillin allergy is reported by 10% to 20 % of patients, but when evaluated only 1% to 2% may have a true allergy. Patients undergoing hematopoietic stem cell transplantation (HSCT) have a high likelihood of requiring beta-lactam antibiot...
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy [0.03%]
白蛋白和CRP的简单评分可预测接受CAR-T治疗的多发性骨髓瘤患者的高毒性分级
Othman S Akhtar,Karnav Modi,Jongphil Kim et al.
Othman S Akhtar et al.
Administration of chimeric-antigen receptor T-cell (CAR-T) therapy is complex and associated with unique toxicities. Identifying patients at risk for inferior outcomes is important for individualized management. The Glasgow-prognostic score...
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome [0.03%]
haploidentical外周血干细胞移植术后环磷酰胺与HLA配型相合的无关供者移植治疗骨髓增生异常综合征的比较研究
Yosuke Nakaya,Hideo Koh,Takaaki Konuma et al.
Yosuke Nakaya et al.
Allogeneic hematopoietic cell transplantation (allo-HCT) is the sole curative therapy for myelodysplastic syndrome (MDS). In the absence of an HLA-matched sibling donor, an HLA-matched unrelated donor (MUD) is considered the leading candida...
Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts [0.03%]
抗CD52单克隆抗体阿仑单抗、双重移植物抗宿主病预防及较低剂量的CD3+T细胞能使接受无关供者外周血造血干细胞或骨髓移植治疗的儿童患者的急性期和慢性期移植物抗宿主病发病率均等化
Su Han Lum,Beki James,Giorgio Ottaviano et al.
Su Han Lum et al.
Data comparing hematopoietic stem cell transplantation (HSCT) using bone marrow (BM) or peripheral blood stem cell (PBSC) grafts in children after alemtuzumab-based conditioning are lacking. We investigated whether in vivo T cell depletion ...
Effect of Conditioning Regimens and Graft-versus-Host Disease Prophylaxis on the Outcomes of Umbilical Cord Blood Transplantation Performed with Cyclophosphamide/Total Body Irradiation-Based Regimens [0.03%]
以环磷酰胺/全身照射为基础的方案对脐带血移植预处理方案和移植物抗宿主病预防的影响
Nobuhiko Imahashi,Naoki Kurita,Takaaki Konuma et al.
Nobuhiko Imahashi et al.
Umbilical cord blood (UCB) is a valuable alternative donor source for allogeneic hematopoietic stem cell transplantation. Various conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens aimed at improving the outcome...